155 related articles for article (PubMed ID: 36044158)
1. Immune checkpoint inhibition improves antimyeloma activity of bortezomib and STING agonist combination in Vk*MYC preclinical model.
Sokolowska O; Rodziewicz-Lurzynska A; Pilch Z; Kedzierska H; Chlebowska-Tuz J; Sosnowska A; Szumera-Cieckiewicz A; Sokol K; Barankiewicz J; Salomon-Perzynski A; Ciepiela O; Lech-Maranda E; Golab J; Nowis D
Clin Exp Med; 2023 Sep; 23(5):1563-1572. PubMed ID: 36044158
[TBL] [Abstract][Full Text] [Related]
2. Transplantation of autologous bone marrow pre-loaded
Villa NY; Rahman MM; Mamola J; Sharik ME; de Matos AL; Kilbourne J; Lowe K; Daggett-Vondras J; D'Isabella J; Goras E; Chesi M; Bergsagel PL; McFadden G
Oncotarget; 2022; 13():490-504. PubMed ID: 35251496
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model.
Thirukkumaran CM; Shi ZQ; Nuovo GJ; Luider J; Kopciuk KA; Dong Y; Mostafa AA; Thakur S; Gratton K; Yang A; Chin AC; Coffey MC; Jimenez-Zepeda VH; Stewart D; Chesi M; Bergsagel PL; Morris D
Blood Adv; 2019 Mar; 3(5):797-812. PubMed ID: 30850386
[TBL] [Abstract][Full Text] [Related]
4. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation.
Gulla A; Morelli E; Samur MK; Botta C; Hideshima T; Bianchi G; Fulciniti M; Malvestiti S; Prabhala RH; Talluri S; Wen K; Tai YT; Richardson PG; Chauhan D; Sewastianik T; Carrasco RD; Munshi NC; Anderson KC
Blood Cancer Discov; 2021 Sep; 2(5):468-483. PubMed ID: 34568832
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of anti-vascular therapy with STING agonist depends on the tumor microenvironment context.
Czapla J; Drzyzga A; Matuszczak S; Cichoń T; Rusin M; Jarosz-Biej M; Pilny E; Smolarczyk R
Front Oncol; 2023; 13():1249524. PubMed ID: 37655095
[TBL] [Abstract][Full Text] [Related]
7. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation.
Bariana M; Cassella E; Rateshwar J; Ouk S; Liou HC; Heller C; Colorado I; Feinman R; Makhdoom A; Siegel DS; Heller G; Tuckett A; Mondello P; Zakrzewski JL
Mol Cancer Ther; 2022 Dec; 21(12):1798-1809. PubMed ID: 36190955
[TBL] [Abstract][Full Text] [Related]
9. Improvement of STING-mediated cancer immunotherapy using immune checkpoint inhibitors as a game-changer.
Lee SE; Jang GY; Lee JW; Park SH; Han HD; Park YM; Kang TH
Cancer Immunol Immunother; 2022 Dec; 71(12):3029-3042. PubMed ID: 35610387
[TBL] [Abstract][Full Text] [Related]
10. Homoharringtonine enhances bortezomib antimyeloma activity in myeloma cells adhesion to bone marrow stromal cells and in SCID mouse xenografts.
Chen P; Yuan Q; Yang H; Wen X; You P; Hou D; Xie J; Cheng Y; Huang H
Leuk Res; 2017 Jun; 57():119-126. PubMed ID: 28463768
[TBL] [Abstract][Full Text] [Related]
11. STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-PD-1 therapy resistance.
Li T; Zhang W; Niu M; Wu Y; Deng X; Zhou J
Front Immunol; 2024; 15():1342647. PubMed ID: 38550593
[TBL] [Abstract][Full Text] [Related]
12. Immunosurveillance and therapy of multiple myeloma are CD226 dependent.
Guillerey C; Ferrari de Andrade L; Vuckovic S; Miles K; Ngiow SF; Yong MC; Teng MW; Colonna M; Ritchie DS; Chesi M; Bergsagel PL; Hill GR; Smyth MJ; Martinet L
J Clin Invest; 2015 May; 125(5):2077-89. PubMed ID: 25893601
[TBL] [Abstract][Full Text] [Related]
13. Runx2 Deficiency in Osteoblasts Promotes Myeloma Resistance to Bortezomib by Increasing TSP-1-Dependent TGFβ1 Activation and Suppressing Immunity in Bone Marrow.
Zhang C; Xu X; Trotter TN; Gowda PS; Lu Y; Suto MJ; Javed A; Murphy-Ullrich JE; Li J; Yang Y
Mol Cancer Ther; 2022 Feb; 21(2):347-358. PubMed ID: 34907087
[TBL] [Abstract][Full Text] [Related]
14. Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis.
Oudaert I; Satilmis H; Vlummens P; De Brouwer W; Maes A; Hose D; De Bruyne E; Ghesquière B; Vanderkerken K; De Veirman K; Menu E
J Exp Clin Cancer Res; 2022 Feb; 41(1):45. PubMed ID: 35105345
[TBL] [Abstract][Full Text] [Related]
15. The lipid platform increases the activity of STING agonists to synergize checkpoint blockade therapy against melanoma.
Li K; Ye Y; Liu L; Sha Q; Wang X; Jiao T; Zhang L; Wang J
Biomater Sci; 2021 Feb; 9(3):765-773. PubMed ID: 33201161
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal preclinical magnetic resonance imaging of diffuse tumor burden in intramedullary myeloma following bortezomib therapy.
Hathi DK; Engelbach JA; Hillengass J; Veis D; Achilefu S; Garbow JR; Shokeen M
NMR Biomed; 2019 Sep; 32(9):e4122. PubMed ID: 31206946
[TBL] [Abstract][Full Text] [Related]
17. Carbon ion irradiation induces DNA damage in melanoma and optimizes the tumor microenvironment based on the cGAS-STING pathway.
Guo Y; Shen R; Wang F; Wang Y; Xia P; Wu R; Liu X; Ye W; Tian Y; Wang D
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6315-6328. PubMed ID: 36745223
[TBL] [Abstract][Full Text] [Related]
18. STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer.
Ghaffari A; Peterson N; Khalaj K; Vitkin N; Robinson A; Francis JA; Koti M
Br J Cancer; 2018 Aug; 119(4):440-449. PubMed ID: 30046165
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease.
Nyman JS; Merkel AR; Uppuganti S; Nayak B; Rowland B; Makowski AJ; Oyajobi BO; Sterling JA
Bone; 2016 Oct; 91():81-91. PubMed ID: 27423464
[TBL] [Abstract][Full Text] [Related]
20. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines.
Barbosa RSS; Dantonio PM; Guimarães T; de Oliveira MB; Fook Alves VL; Sandes AF; Fernando RC; Colleoni GWB
Biochem Biophys Res Commun; 2019 Nov; 519(3):597-604. PubMed ID: 31540690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]